Transaction DateRecipientSharesTypePriceValue
22nd September 2020Advisors Llc Perceptive1,058,824Open or private purchase$17.00$18,000,008.00
22nd September 2020Advisors Llc Perceptive1,644,785Conversion of derivative$0.00
15th September 2020Advisors Llc Perceptive2,911,764Open or private purchase$4.25$12,374,997.00
14th September 2020Advisors Llc Perceptive1,800,000Open or private purchase$11.00$19,800,000.00
14th September 2020Advisors Llc Perceptive400,000Open or private purchase$40.00$16,000,000.00
10th September 2020Advisors Llc Perceptive200,000Open or private purchase$11.24$2,248,000.00
9th July 2020Advisors Llc Perceptive3,200,000Open or private purchase$4.25$13,600,000.00
30th June 2020Todd C Brady8,418Grant/award etc.$0.00
22nd June 2020Advisors Llc Perceptive1,750,000Open or private purchase$2.00$3,500,000.00
9th June 2020Advisors Llc Perceptive2,702,702Open or private purchase$1.85$4,999,998.70
Aldeyra Therapeutics
Aldeyra Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Aldeyra Therapeutics, Inc. is a biotechnology company. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases.

Ticker: ALDX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1341235
Employees: 20
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags